NYSE · NVS
Novartis AG financials
$145.71−0.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $56.67B | $51.72B | $46.66B | $43.46B | $43.97B | $49.90B | $48.68B | $46.10B | $43.40B | $49.44B |
| Gross profit | $42.98B | $38.90B | $34.19B | $31.88B | $32.24B | $34.78B | $34.25B | $31.59B | $29.77B | $31.92B |
| Gross margin | 75.8% | 75.2% | 73.3% | 73.4% | 73.3% | 69.7% | 70.4% | 68.5% | 68.6% | 64.6% |
| Operating income | $16.18B | $13.37B | $8.00B | $7.95B | $10.06B | $10.15B | $9.09B | $9.38B | $8.92B | $8.69B |
| Net income | $13.98B | $11.94B | $14.85B | $6.96B | $24.02B | $8.07B | $11.73B | $12.61B | $7.70B | $6.71B |
| Net margin | 24.7% | 23.1% | 31.8% | 16.0% | 54.6% | 16.2% | 24.1% | 27.4% | 17.7% | 13.6% |
| Diluted EPS | $7.15 | $5.87 | $7.10 | $3.17 | $10.63 | $3.52 | $5.06 | $5.38 | $3.25 | $2.80 |
| EBITDA | $16.18B | $13.37B | $8.00B | $7.95B | $10.06B | $10.15B | $9.09B | $9.38B | $8.92B | $8.69B |
| Operating cash flow | $19.14B | $17.62B | $14.46B | $14.24B | $15.07B | $13.65B | $13.63B | $14.27B | $12.62B | $11.47B |
| Free cash flow | $17.60B | $16.25B | $13.40B | $13.32B | $14.01B | $12.38B | $12.25B | $13.02B | $11.30B | $9.61B |
| Diluted shares | 1,955.0M | 2,035.0M | 2,092.0M | 2,197.0M | 2,260.0M | 2,296.0M | 2,319.0M | 2,344.0M | 2,371.0M | 2,400.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.44B | $11.46B | $13.39B | $7.52B | $12.41B | $9.66B |
| Short-term investments | $0.00 | $0.00 | $1.03B | $11.41B | $15.92B | $1.91B |
| Total debt | $5.60B | $8.23B | $18.44B | $26.18B | $29.20B | $36.04B |
| Total assets | $110.95B | $102.25B | $99.94B | $117.45B | $131.79B | $127.78B |
| Total liabilities | $64.40B | $58.12B | $53.20B | $58.03B | $63.97B | $71.11B |
| Shareholders' equity | $46.55B | $44.13B | $46.75B | $59.42B | $67.82B | $56.67B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology